Allianz Asset Management’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

Allianz Asset Management’s Portfolio NWBO Stock Details NWBO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-169,950	Closed	-$1.14M	–	2449
2014 Q2	$1.14M	Sell	169,950 -17,550	-9%	-$112K	﹤0.01%	1365
2014 Q1	$1.36M	Hold	187,500	–	–	﹤0.01%	1320
2013 Q4	$707K	Hold	187,500	–	–	﹤0.01%	1468
2013 Q3	$630K	Hold	187,500	–	–	﹤0.01%	1468
2013 Q2	$626K	Buy	+187,500	New	+$680K	﹤0.01%	1445

Other funds holding NWBO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Allianz Asset Management's NWBO Position: Q3 2014 in Review

Allianz Asset Management sold out of Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q3 2014, closing a stake of 169,950 shares — an estimated $1.14M sold.

Allianz Asset Management first reported a position in NWBO in Q2 2013 and held it in 5 quarters. The position peaked at $1.36M in Q1 2014. 71 funds tracked by Wall St. Rank hold NWBO as of Q3 2014.

Allianz Asset Management reported no remaining Northwest Biotherapeutics, Inc. Common stock position as of Q3 2014 after selling out during the quarter.
Allianz Asset Management sold 169,950 Northwest Biotherapeutics, Inc. Common stock shares in Q3 2014, an estimated $1.14M.
Allianz Asset Management first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q2 2013 and held it in 5 quarters.
Allianz Asset Management's Northwest Biotherapeutics, Inc. Common stock position peaked at $1.36M in Q1 2014.
71 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q3 2014.

Based on Allianz Asset Management's 13F filing for Q3 2014, filed 14 Nov 2014.